Skip to main content

Advertisement

SpringerLink
Log in

SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013

  • Clinical Guides in Oncology
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

The purpose of this article is to update our previous work on the treatment and follow-up in early breast cancer. In this new version we have classified a treatment by immunohistochemistry subtypes of breast cancer. Latest advances in the management of this disease have been compiled, either in the adjuvant and neoadjuvant setting or chemotherapy and hormonal treatment. This review is presented in an easy way for oncologist, fellows and for other specialties.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.

    Article  Google Scholar 

  2. Early Breast Cancer Trialists’ Comparison between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100000 women in 123 randomised trials. Lancet 2012;379:432–44.

    Google Scholar 

  3. Davies Ch, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16.

    Article  PubMed  CAS  Google Scholar 

  4. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J; Panel Members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22:1736–1747.

  5. ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women for early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131–9.

    Article  Google Scholar 

  6. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757.

    Google Scholar 

  7. Coombes Ch, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–92.

    Article  PubMed  CAS  Google Scholar 

  8. The BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361:776–76.

    Google Scholar 

  9. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–18.

    Article  PubMed  CAS  Google Scholar 

  10. De Laurentiis M, Cancello G, D’Agostino D, Giuliano M, Giordano A, Montagna E, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008;26:44–53.

    Article  PubMed  Google Scholar 

  11. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–13.

    Article  PubMed  CAS  Google Scholar 

  12. Jones SE, Savin MA, Holmes FA, O’Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24:5381–7.

    Article  PubMed  CAS  Google Scholar 

  13. Perez EA, Romond EH, SumanVJ, Jeong JH, Davidson NE, Geyer CE Jr, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29:3366–73.

  14. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER-2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12:236–44.

    Article  PubMed  CAS  Google Scholar 

  15. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER-2 positive breast cancer. N Engl J Med. 2011;365:1273–83.

    Article  PubMed  CAS  Google Scholar 

  16. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796–804.

    Article  Google Scholar 

  17. von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, et al. Integrating bevacizumab, everolimus and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of GeparQuinto trial. Ann Oncol. 2011;22:301–6.

    Article  Google Scholar 

  18. Ellis M, Tao Y, Luo J, A’Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on post neoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100:1380–8.

    Article  PubMed  CAS  Google Scholar 

  19. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (NOAH trial): a randomized controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377–84.

    Article  PubMed  CAS  Google Scholar 

  20. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (Neoaltto): a randomised, open-label, multicenter phase III trial. Lancet. 2012;379:633–40.

    Article  PubMed  CAS  Google Scholar 

  21. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory or early HER2-positive breast cancer (NeosPhere): a randomized multicentre open-label phase 2 trial. Lancet Oncol. 2012;13:25–32.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest relating to the publication of this manuscript.

Author information

Authors and Affiliations

  1. Medical Oncology Department, Hospital Dr. Josep Trueta, Institut Català d’Oncologia (ICO), Girona, Spain

    S. Del Barco

  2. Medical Oncology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain

    E. Ciruelos

  3. Medical Oncology Department, Hospital de Parc de Salut Mar, Barcelona, Spain

    I. Tusquets

  4. Medical Oncology Department, Hospital Virgen del Rocío, Sevilla, Spain

    M. Ruiz

  5. Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    A. Barnadas

Authors
  1. S. Del Barco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Ciruelos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Tusquets
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Barnadas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Barnadas.

Appendix: Clinical Guideline Working Group on behalf of the Spanish Society of Medical Oncology (SEOM) Executive Committee 2011–2013

Appendix: Clinical Guideline Working Group on behalf of the Spanish Society of Medical Oncology (SEOM) Executive Committee 2011–2013

Juan Jesús Cruz, Pilar Garrido, Agustí Barnadas, Pablo Borrega, Francisco Javier Barón, Elvira del Barco, Rocio García-Carbonero, Jesús Garcia-Mata, Encarnación Gonzalez, Pilar Lianes, Antonio Llombart y Fernando Rivera.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Del Barco, S., Ciruelos, E., Tusquets, I. et al. SEOM Clinical Guidelines for the systemic treatment of early breast cancer 2013. Clin Transl Oncol 15, 1011–1017 (2013). https://doi.org/10.1007/s12094-013-1084-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-013-1084-3

Keywords

Search

Navigation